Evaluation of the effect on heart rate variability of a β2-adrenoceptor agonist and antagonist using non-linear scatterplot and sequence methods

British Journal of Clinical Pharmacology

Volumn 47, Issue 2, 1999, Pages 157-166

  Hanratty, C G ^a   Silke, B ^a   Riddell, J G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

adrenoceptor; Heart rate variability; Non linear; Partial agonist; Scatterplot

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; SALBUTAMOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INHIBITION; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; ALBUTEROL; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HEART RATE; HUMANS; MALE; PLACEBOS; PROPANOLAMINES; SLEEP; STATISTICS;

EID: 0032987536     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00862.x     Document Type: Article

References (44)

1. Kleiger RE, Miller JP, Bigger JT, Moss AJ. The Multicenter Post-Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256-262.
2. Malik M, Farrell T, Cripps T, Camm AJ. Heart rate variability in relation to prognosis after myocardial infarction: selection of optimal processing techniques. Eur Heart J 1989; 10: 1060-1074.
3. Bigger JT, Fleiss JL, Steinman R, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164-171.
4. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med 1976; 294: 1165-1170.
5. Spiers JP, Silke B, McDermott U, Shanks RG, Harron DWG. Time and frequency domain assessment of heart rate variability: a theoretical and clinical appreciation. Clin Autonom Res 1993; 3: 145-158.
6. Norwegian Multicentre Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-807.
7. Beta-blocker Heart attack Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. J Am Med Ass 1982; 247: 1707-1714.
8. Molgaard H, Mickley H, Pless P, Bjerregaard P, Moller M. Effects of metoprolol on heart rate variability in survivors of acute myocardiol infarction. Am J Cardiol 1993; 71: 1357-1359.
9. Sandrone G, Mortara A, Torzillo D, La Rovere MT, Malliani A, Lombardi F. Effects of beta blockers (atenolol or metoprolol) on heart rate variability after acute myocardial infaction. Am J Cardiol 1994; 74: 340-345.
10. Lipworth BJ, Grove A. Partial beta-adrenoceptor agonists revisited. Br J Clin Pharmacol 1997; 43: 9-14.
11. Silke B, Riddell JG. Effects of beta-adrenoceptor agonists and antagonists on heart-rate variability assessed using summary statistics and nonlinear procedures. J Cardiovasc Pharmacol 1997; 30: 817-823.
12. Camm J, Malik M. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Report of Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354-381.
13. Raetz SL, Richard CA, Garfinkel A, Harper RM. Dynamic characteristics of cardiac R-R intervals during sleep and waking states. Sleep 1991; 14: 526-533.
14. Schechtman VL, Raetz SL, Harper RK, Garfinkel A, Wilson AJ, Southall DP. Dynamic analysis of cardiac R-R intervals in normal infants and in infants who subsequently succumbed to the sudden infant death syndrome. Paed Res 1992; 31: 606-612.
15. Hagerman I, Berglund M, Lorin M, Nowak J, Sylven C. Chaos-related deterministic regulation of heart rate variability in time- and frequency domains: effects of autonomic blockade and exercise. Cardiovasc Res 1996; 31: 410-418.
16. Hnatkova K, Copie X, Staunton A, Malik M. Numeric processing of Lorenz plots of R-R intervals from long-term ECG's - comparison with time-domain measures of heart rate variability for risk stratification after myocardial infarction. J Electrocardiography 1995; 28: 74-80.
17. Copie X, Leheuzey JY, Iliow MC, et al. Correlation between time-domain measures of heart rate variability and scatterplots in post-infarction patients. Pace-Pacing and Clinical Electrophysiology 1996; 19: 342-347.
18. Kamen PW, Krum H, Tonkin AM. Poincare plot of heart rate variability allows quantitative display of parasympathetic nervous activity in humans. Clin Sci 1996; 91: 201-208.
19. McCaffrey PM, Riddell JG, Shanks RG. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118, 511. J Cardiovasc Pharmacol 1988; 11: 543-551.
20. Arnold JMO, O'Conner PC, Riddell JG, Harron DWG, Shanks RG, McDevitt DG. Effects of the beta-2 antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol 1985; 19: 619-630.
21. McCaffrey PM, Riddell JG, Shanks RG. An assessment of the partial agonist activity of Ro 31 1118, flusoxolol and pindolol in man. Br J Clin Pharmacol 1987; 24: 571-580.
22. Wagner J, Reinhardt D, Schumann HJ. Comparison of the bronchodilator and cardiovascular actions of isoprenaline. Th 1165a, terbutaline and salbutamol in cats and isolated organ preparations. Res Exp Med 1973; 162: 49-62.
23. O'Donnell SR. An examination of some beta-adrenoceptor stimulants for selectivity using the isolated trachea and atria of the guinea pig. Eur J Pharmacol 1972; 19: 371-379.
24. Bilski AJ, Halliday SE, Fitzgerald JD, Wale JL. The pharmacology of a beta-2 adrenoceptor antagonist (ICI 118,551). J Cardiovasc Pharmacol 1983; 5: 430-437.
25. Harry JD, Norris SC, Percival GC, Young J. The dose in humans at which ICI 118,551 (a selective beta-2 adrenoceptor blocking agent) demonstrates blockade of beta-1 adrenoceptors. Clin Pharmacol Ther 1988; 43: 492-498.
26. Malik M, Cripps T, Farrell T, Camm AJ. Prognostic value of heart rate variability after myocardial infarction. A comparison of different data processing methods. Med Biol Eng Comput 1989; 27: 603-611.
27. SPSS I. SPSS for Windows Users Guide. Chicago, IL 60611: Norusis/SPSS Inc., 1993.
28. Pousset F, Copie X, LeChat P, et al. Effects of bisoprolol on heart-rate variability in heart-failure. Am J Cardiol 1996; 77: 612-617.
29. Altman DG. Two way analysis of variance. In Practical Statistics for Medical Research. London: Chapman & Hall, 1992: 334-336.
30. Grove A, McFarlane LC, Lipworth BJ. Expression of the beta-2 partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995; 50: 134-138.
31. Hall JA, Petch MC, Brown MJ. Intracoronary injections of salbutamol demonstrate the presence of functional beta-2 adrenoceptors in the human heart. Circ Res 1989; 65: 546-553.
32. Lipworth BJ, Brown RA, McDevitt DJ. Assessment of airways, tremor, and chronotropic responses to inhaled salbutamol in the quantification of beta-2 adrenoceptor blockade. Br J Clin Pharmacol 1989; 28: 95-102.
33. Cook JR, Bigger JT, Kleiger RE, Fleiss JL, Steinman RC, Rolnitzky LM. Effect of atenolol and diltiazem on heart rate variability in normal persons. J Am Coll Cardiol 1991; 17: 480-484.
34. Schweizer MW, Brachmann J, Kirchner U, et al. Heart rate variability in time and frequency domains: effects of gallopamil, nifedipine, and metoprolol compared with placebo. Br Heart J 1993; 70: 252-258.
35. Niemela MJ, Airaksinen KE, Huikuri HV. Effect of beta- blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 1994; 23: 1370-1377.
36. Hohnloser SH, Klingenheben T, Zabel M, Just H. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias. Am J Cardiol 1993; 72: 67A-71A.
37. Brouwer J, Viersma JW, Vanveldhuisen DJ, et al. Usefulness of heart-rate variability in predicting drug efficacy (metoprolol vs diltiazem) in patients with stable angina. Am J Cardiol 1995; 76: 759-763.
38. Keeley EC, Lange RA, Hillis LD, Joglar JA, Page RL. Correlation between time-domain measures of heart rate variability and scatterplots in patients with healed myocardial infarcts and the influence of metoprolol. Am J Cardiol 1997; 79: 412-414.
39. Stein PK, Rottman JN, Bosner MS, Conger BM, Kleiger RE. Effects of pindolol and labetalol on heart rate variability in normal subjects. Ambul Monit 1995; 8: 171-178.
40. Hadfield SE, Slee S-J, Snow HM. The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog. Br J Clin Pharmacol 1989; 28: 78S-81S.
41. Jartti T, Kaila T, Tahvanainen K, Kuusela T, Vanto T, Valimaki I. The acute effects of inhaled salbutamol on the beat-to beat variability of heart rate and blood pressure assessed by spectral analysis. Br J Clin Pharmacol 1997; 43: 421-428.
42. Jartti TT, Kuusela TA, Kaila TJ, Tahvanainen KUO, Valimaki AT. The dose-response effects of terbutaline on the variability, approximate entropy and fractal dimension of heart rate and blood pressure. Br J Clin Pharmacol 1998; 45: 277-285.
43. Wheeldon NM, McDevitt DG, Lipworth BJ. Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. Br J Clin Pharmacol 1992; 34: 337-343.
44. Brouwer J, van Veldhuisen DJ, Man in't Veld AJ, et al. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicentre Trial Study Group. J Am Coll Cardiol 1996; 28: 1183-1189.